A Prospective Observational Study of 1st and 2nd Line Vectibix Use in KRAS/NRAS-wt mCRC Patients to Evaluate Pattern of Use and Overall Response Rates
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms VISION
- Sponsors Amgen
- 01 Dec 2017 Planned End Date changed from 30 Dec 2018 to 30 Nov 2018.
- 01 Dec 2017 Planned primary completion date changed from 30 Dec 2018 to 30 Nov 2018.
- 01 Dec 2017 Status changed from recruiting to active, no longer recruiting.